Page last updated: 2024-11-04

ropinirole and Movement Disorders

ropinirole has been researched along with Movement Disorders in 7 studies

Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.

Research Excerpts

ExcerptRelevanceReference
"Ropinirole is a non-ergoline selective D2 dopamine agonist."1.34[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. ( Angersbach, D; Buchwald, B; Jost, WH, 2007)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Wang, Y1
Bouabid, S1
Darvas, M1
Zhou, FM1
Kim, HJ1
Park, SY1
Cho, YJ1
Hong, KS1
Cho, JY1
Seo, SY1
Lee, DH1
Jeon, BS1
Hersh, BP1
Earl, NL1
Hauser, RA1
Stacy, M1
Salamone, JD1
Carlson, BB1
Rios, C1
Lentini, E1
Correa, M1
Wisniecki, A1
Betz, A1
Buchwald, B1
Angersbach, D1
Jost, WH1
Stockwell, KA1
Virley, DJ1
Perren, M1
Iravani, MM1
Jackson, MJ1
Rose, S1
Jenner, P1
Rascol, O1
Lees, AJ1
Senard, JM1
Pirtosek, Z1
Brefel, C1
Montastruc, JL1
Fuell, D1

Trials

2 trials available for ropinirole and Movement Disorders

ArticleYear
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
    Movement disorders : official journal of the Movement Disorder Society, 2010, May-15, Volume: 25, Issue:7

    Topics: Aged; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles;

2010
A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Advances in neurology, 1996, Volume: 69

    Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Movem

1996

Other Studies

5 other studies available for ropinirole and Movement Disorders

ArticleYear
The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
    Experimental neurology, 2020, Volume: 333

    Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Homeodomain Proteins; Indoles; Male; Mice; Mice

2020
Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
    Journal of the neurological sciences, 2009, Dec-15, Volume: 287, Issue:1-2

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Comorbidity; Disability Evaluation;

2009
Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.
    Behavioural brain research, 2005, Jan-30, Volume: 156, Issue:2

    Topics: Analysis of Variance; Animals; Cholinergic Agents; Disease Models, Animal; Dopamine Agonists; Dose-R

2005
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Fortschritte der Neurologie-Psychiatrie, 2007, Volume: 75, Issue:4

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Disabi

2007
Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Experimental neurology, 2008, Volume: 211, Issue:1

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Drug Administrati

2008
chemdatabank.com